# 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

> **NCT01517308** · PHASE3 · WITHDRAWN · sponsor: **Federico II University**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** pegylated interferon alpha 2a + ribavirin

## Key facts

- **NCT ID:** NCT01517308
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-05
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial
- **Last updated:** 2012-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01517308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01517308, "24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01517308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*